Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines.

Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, Sandalcioglu IE, Neyazi B, Moritz T, Meyer J, Rossig C, Altvater B, Eiz-Vesper B, Morgan MA, Abken H, Schambach A.

Cancers (Basel). 2020 Feb 6;12(2). pii: E375. doi: 10.3390/cancers12020375.

2.

Requirement for YAP1 signaling in myxoid liposarcoma.

Trautmann M, Cheng YY, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S.

EMBO Mol Med. 2019 May;11(5). pii: e9889. doi: 10.15252/emmm.201809889.

3.

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.

Kailayangiri S, Altvater B, Lesch S, Balbach S, Göttlich C, Kühnemundt J, Mikesch JH, Schelhaas S, Jamitzky S, Meltzer J, Farwick N, Greune L, Fluegge M, Kerl K, Lode HN, Siebert N, Müller I, Walles H, Hartmann W, Rossig C.

Mol Ther. 2019 May 8;27(5):933-946. doi: 10.1016/j.ymthe.2019.02.014. Epub 2019 Feb 23.

PMID:
30879952
4.

SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.

Isfort I, Cyra M, Elges S, Kailayangiri S, Altvater B, Rossig C, Steinestel K, Grünewald I, Huss S, Eßeling E, Mikesch JH, Hafner S, Simmet T, Wozniak A, Schöffski P, Larsson O, Wardelmann E, Trautmann M, Hartmann W.

Clin Cancer Res. 2019 Jun 15;25(12):3718-3731. doi: 10.1158/1078-0432.CCR-17-3553. Epub 2019 Feb 27.

PMID:
30814111
5.

Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.

Trautmann M, Cyra M, Isfort I, Jeiler B, Krüger A, Grünewald I, Steinestel K, Altvater B, Rossig C, Hafner S, Simmet T, Becker J, Åman P, Wardelmann E, Huss S, Hartmann W.

Mol Cancer Ther. 2019 Apr;18(4):834-844. doi: 10.1158/1535-7163.MCT-18-0763. Epub 2019 Feb 20.

6.

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers.

Rossig C, Kailayangiri S, Jamitzky S, Altvater B.

Front Oncol. 2018 Nov 12;8:513. doi: 10.3389/fonc.2018.00513. eCollection 2018. Review.

7.

T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.

Spurny C, Kailayangiri S, Altvater B, Jamitzky S, Hartmann W, Wardelmann E, Ranft A, Dirksen U, Amler S, Hardes J, Fluegge M, Meltzer J, Farwick N, Greune L, Rossig C.

Oncotarget. 2017 Dec 22;9(5):6536-6549. doi: 10.18632/oncotarget.23815. eCollection 2018 Jan 19.

8.

Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.

Spurny C, Kailayangiri S, Jamitzky S, Altvater B, Wardelmann E, Dirksen U, Hardes J, Hartmann W, Rossig C.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26719. Epub 2017 Sep 4.

PMID:
28868758
9.

FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.

Trautmann M, Menzel J, Bertling C, Cyra M, Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C, Fröhling S, Hafner S, Simmet T, Åman P, Wardelmann E, Huss S, Hartmann W.

Clin Cancer Res. 2017 Oct 15;23(20):6227-6238. doi: 10.1158/1078-0432.CCR-17-0130. Epub 2017 Jun 21.

10.

Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Kailayangiri S, Altvater B, Spurny C, Jamitzky S, Schelhaas S, Jacobs AH, Wiek C, Roellecke K, Hanenberg H, Hartmann W, Wiendl H, Pankratz S, Meltzer J, Farwick N, Greune L, Fluegge M, Rossig C.

Oncoimmunology. 2016 Oct 28;6(1):e1250050. doi: 10.1080/2162402X.2016.1250050. eCollection 2017.

11.

Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.

Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S, Clifton-Hadley L, Champion K, Sattar Z, Popova B, Hackshaw A, Smith P, Roberts T, Biagi E, Dreno B, Rousseau R, Kailayangiri S, Ahlmann M, Hough R, Kremens B, Sauer MG, Veys P, Goulden N, Cummins M, Amrolia PJ.

Leukemia. 2017 May;31(5):1087-1095. doi: 10.1038/leu.2017.39. Epub 2017 Jan 27.

PMID:
28126984
12.

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.

Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M.

Bone Marrow Transplant. 2017 Feb;52(2):317-320. doi: 10.1038/bmt.2016.274. Epub 2016 Nov 28. No abstract available.

PMID:
27892950
13.

Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Roellecke K, Virts EL, Einholz R, Edson KZ, Altvater B, Rossig C, von Laer D, Scheckenbach K, Wagenmann M, Reinhardt D, Kramm CM, Rettie AE, Wiek C, Hanenberg H.

Gene Ther. 2016 Jul;23(7):615-26. doi: 10.1038/gt.2016.38. Epub 2016 May 19.

PMID:
27092941
14.

Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells.

Jamitzky S, Krueger AC, Janneschuetz S, Piepke S, Kailayangiri S, Spurny C, Rossig C, Altvater B.

Pediatr Blood Cancer. 2015 Nov;62(11):1979-85. doi: 10.1002/pbc.25619. Epub 2015 Jul 1.

PMID:
26131572
15.

Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Schliemann C, Gutbrodt KL, Kerkhoff A, Pohlen M, Wiebe S, Silling G, Angenendt L, Kessler T, Mesters RM, Giovannoni L, Schäfers M, Altvater B, Rossig C, Grünewald I, Wardelmann E, Köhler G, Neri D, Stelljes M, Berdel WE.

Cancer Immunol Res. 2015 May;3(5):547-56. doi: 10.1158/2326-6066.CIR-14-0179. Epub 2015 Feb 11.

16.

Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.

Altvater B, Kailayangiri S, Theimann N, Ahlmann M, Farwick N, Chen C, Pscherer S, Neumann I, Mrachatz G, Hansmeier A, Hardes J, Gosheger G, Juergens H, Rossig C.

Cancer Immunol Immunother. 2014 Oct;63(10):1047-60. doi: 10.1007/s00262-014-1574-3. Epub 2014 Jun 28.

PMID:
24973179
17.

Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.

Leuchte K, Altvater B, Hoffschlag S, Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J, Dirksen U, Juergens H, Kailayangiri S, Rossig C.

Oncol Rep. 2014 Aug;32(2):845-52. doi: 10.3892/or.2014.3269. Epub 2014 Jun 13.

PMID:
24927333
18.

High proportions of CD4⁺ T cells among residual bone marrow T cells in childhood acute lymphoblastic leukemia are associated with favorable early responses.

Lustfeld I, Altvater B, Ahlmann M, Ligges S, Brinkrolf P, Rosemann A, Moericke A, Rossig C.

Acta Haematol. 2014;131(1):28-36. doi: 10.1159/000351429. Epub 2013 Sep 10.

19.

Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging.

Liebsch L, Kailayangiri S, Beck L, Altvater B, Koch R, Dierkes C, Hotfilder M, Nagelmann N, Faber C, Kooijman H, Ring J, Vieth V, Rossig C.

Br J Cancer. 2013 Aug 6;109(3):658-66. doi: 10.1038/bjc.2013.356. Epub 2013 Jul 9.

20.

Zoledronic acid negatively affects the expansion of in vitro activated human NK cells and their cytolytic interactions with Ewing sarcoma cells.

Mueller SK, Altvater B, Chen C, Kailayangiri S, Ahlmann M, Dirksen U, Juergens H, Rossig C.

Oncol Rep. 2013 Jun;29(6):2348-54. doi: 10.3892/or.2013.2350. Epub 2013 Mar 19.

PMID:
23525469
21.

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting.

Kailayangiri S, Altvater B, Meltzer J, Pscherer S, Luecke A, Dierkes C, Titze U, Leuchte K, Landmeier S, Hotfilder M, Dirksen U, Hardes J, Gosheger G, Juergens H, Rossig C.

Br J Cancer. 2012 Mar 13;106(6):1123-33. doi: 10.1038/bjc.2012.57. Epub 2012 Feb 28.

22.

Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.

Altvater B, Pscherer S, Landmeier S, Kailayangiri S, Savoldo B, Juergens H, Rossig C.

Cancer Immunol Immunother. 2012 Mar;61(3):385-96. doi: 10.1007/s00262-011-1111-6. Epub 2011 Sep 18.

PMID:
21928126
23.

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.

Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S, Gerss J, Maecker HT, Berdel WE, Juergens H, Lee PP, Rossig C.

Leukemia. 2012 Mar;26(3):465-74. doi: 10.1038/leu.2011.239. Epub 2011 Sep 9.

PMID:
21904381
24.

Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo.

Landmeier S, Altvater B, Pscherer S, Meltzer J, Sebire N, Pule M, Vera J, Hotfilder M, Juergens H, Vormoor J, Rossig C.

Leukemia. 2010 May;24(5):1080-4. doi: 10.1038/leu.2010.38. Epub 2010 Mar 11. No abstract available.

PMID:
20220773
25.

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C.

Clin Cancer Res. 2009 Aug 1;15(15):4857-66. doi: 10.1158/1078-0432.CCR-08-2810. Epub 2009 Jul 28.

26.

A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease.

Brinkrolf P, Landmeier S, Altvater B, Chen C, Pscherer S, Rosemann A, Ranft A, Dirksen U, Juergens H, Rossig C.

Int J Cancer. 2009 Aug 15;125(4):879-86. doi: 10.1002/ijc.24461.

27.

2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells.

Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M, Rossig C.

Cancer Immunol Immunother. 2009 Dec;58(12):1991-2001. doi: 10.1007/s00262-009-0704-9. Epub 2009 Apr 10.

PMID:
19360406
28.

Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.

Landmeier S, Altvater B, Pscherer S, Juergens H, Varnholt L, Hansmeier A, Bollard CM, Moosmann A, Bisping G, Rossig C.

J Immunother. 2009 Apr;32(3):310-21. doi: 10.1097/CJI.0b013e31819b7c30.

29.

Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.

Landmeier S, Altvater B, Pscherer S, Eing BR, Kuehn J, Rooney CM, Juergens H, Rossig C.

Cancer Res. 2007 Sep 1;67(17):8335-43.

30.

CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.

Altvater B, Pscherer S, Landmeier S, Niggemeier V, Juergens H, Vormoor J, Rossig C.

Clin Exp Immunol. 2006 Jun;144(3):447-57.

31.

Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.

Rossig C, Bär A, Pscherer S, Altvater B, Pule M, Rooney CM, Brenner MK, Jürgens H, Vormoor J.

J Immunother. 2006 Jan-Feb;29(1):21-31.

PMID:
16365597
32.

Adoptive cellular immunotherapy with CD19-specific T cells.

Rössig C, Pscherer S, Landmeier S, Altvater B, Jürgens H, Vormoor J.

Klin Padiatr. 2005 Nov-Dec;217(6):351-6.

PMID:
16307422

Supplemental Content

Loading ...
Support Center